Nanoform Finland Oyj (HEL: NANOFH)
1.850
+0.004 (0.22%)
Aug 30, 2024, 6:29 PM EET
Nanoform Finland Oyj Company Description
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States.
The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients, as well as designs and develops nanoformed drug substance.
It also offers STARMAP, as a secure online portal to perform large numbers of in-silico CESS experiments The company was founded in 2008 and is headquartered in Helsinki, Finland.
Nanoform Finland Oyj
Country | Finland |
Founded | 2008 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 165 |
CEO | Edward Haeggstrom |
Contact Details
Address: Cultivator II Helsinki, 00790 Finland | |
Phone | 358 2937 00150 |
Website | nanoform.com |
Stock Details
Ticker Symbol | NANOFH |
Exchange | Nasdaq Helsinki |
Fiscal Year | January - December |
Reporting Currency | EUR |
ISIN Number | FI4000330972 |
SIC Code | 8731 |
Key Executives
Name | Position |
---|---|
Prof. Edward Olof Haeggstrom | Co-Founder and Chief Executive Officer |
Albert Alexander Haeggstrom | Chief Financial Officer and Director |
Henri von Haartman | Director of Investor Relations |
Peter Hanninen | General Counsel and Chief Development Officer |
Dr. David Rowe | Head of Manufacturing |
Christian Jones | Chief Commercial Officer |
Antonio Da Silva | Chief of Business Operations |
Johanna Kause | Chief Quality Officer |
Dr. Jamie Unwin | Vice President of Strategic Insight |